The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT05961202

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05961202
Other papers using this trial's data
  • The efficacy and safety of hydroxychloroquine in patients with chronic inflammatory cardiomyopathy: a multicenter randomized study (HYPIC trial) BMC medicine, 2025-08-08 DOI, PubMed 40781621, PMC12333291 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05961202. Randomized; single masking; primary purpose treatment. Start 2021-11-01 (actual); primary completion 2024-09-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy
Acronym
HYPIC
Condition
Inflammatory Cardiomyopathy
Condition
Myocarditis
Intervention (Drug)
Hydroxychloroquine
Intervention (Drug)
Prednisolone
Lead sponsor
Tongji Hospital (class: other)
Collaborator
Wuhan Central Hospital (class: other)
Collaborator
Taihe Hospital (class: other)

Record details

Record id
cardio:ct-nct05961202
Content hash
a2000ee727f28034b7dc3dad4b1cb3124fcca73189a328e5c041031aabef59ff